Kontafarma China Holdings Limited logo

Kontafarma China Holdings Limited (1312)

Market Open
12 Aug, 08:00
HKEX HKEX
0. 03
HKD
0
0%
HKD
173.25M Market Cap
- P/E Ratio
- Div Yield
7.42M Volume
- Eps
0.03 HKD
Previous Close
Add Transaction
Day Range
0.03 0.03
Year Range
0.02 0.05
Want to track 1312 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

1312 trading today higher at 0.03 HKD, an increase of 0% from yesterday's close, completing a monthly increase of 3.5714% or 0 HKD. Over the past 12 months, 1312 stock gained 3.5714%.
1312 is not paying dividends to its shareholders.
The last earnings report, released on Aug 26, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Kontafarma China Holdings Limited has completed 2 stock splits, with the recent split occurring on Jan 20, 2015.
The company's stock is traded on one exchange.

1312 Chart

Kontafarma China Holdings Limited (1312) FAQ

What is the stock price today?

The current price is 0.03 HKD.

On which exchange is it traded?

Kontafarma China Holdings Limited is listed on HKEX.

What is its stock symbol?

The ticker symbol is 1312.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 173.25M.

Has Kontafarma China Holdings Limited ever had a stock split?

Kontafarma China Holdings Limited had 2 splits and the recent split was on Jan 20, 2015.

Kontafarma China Holdings Limited Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Chaowen Jiang CEO
HKEX Exchange
G8918D108 CUSIP
Hong Kong Country
655 Employees
- Last Dividend
20 Jan 2015 Last Split
- IPO Date

Overview

Kontafarma China Holdings Limited, originally founded in 1993 and headquartered in Wan Chai, Hong Kong, has evolved from its initial identity as Tongfang Kontafarma Holdings Limited, undergoing a name change in September 2022. Operating as an investment holding company, it has carved out a significant presence in the pharmaceutical industry, particularly focusing on the Mainland China market while also reaching Singapore, Taiwan, and international fronts. The company is recognized for its dual-segment operation, straddling the fields of Pharmaceutical Business and Fitness Business, hence embodying a unique blend of healthcare and wellness services. Kontafarma China Holdings Limited is a part of China Health Management Investment Limited, indicating a backing by substantial investment and management expertise in the health sector. Its business operations extend to manufacturing and selling prescription drugs, which include both chemical drugs and traditional Chinese medicines, underlining the company's roots and commitment to merging traditional and modern medicinal practices.

Products and Services

The range of products and services offered by Kontafarma China Holdings Limited is diverse, spanning across pharmaceutical and fitness domains:

  • Prescription Drugs: The company specializes in the production and distribution of a wide array of chemical drugs and traditional Chinese medicines, catering to various medical needs and conditions. These prescription drugs are made available within Mainland China and beyond, focusing on quality and efficacy.
  • Fitness and Yoga Centers: Kontafarma operates several fitness and yoga centers, providing tailored wellness and physical conditioning programs. These centers are designed to enhance health and well-being through personalized fitness routines and yoga practices, reflecting the company’s commitment to holistic health.
  • Franchise Business: The company leverages the franchise model to expand its reach in the health and fitness industry, offering franchise opportunities that contribute to its growth and accessibility to a broader demographic.
  • Consultation Services: Kontafarma offers expert consultation services in the domains of fitness and health, aiming to provide professional advice and guidance for individuals seeking to improve their health and lifestyle. These services emphasize the importance of informed health decisions and personalized care.
  • Research and Development (R&D): A crucial wing of Kontafarma lies in its ongoing research and development activities, focusing on the creation and improvement of medical products. Through its R&D efforts, the company aims to innovate and introduce effective healthcare solutions that meet evolving medical needs.
  • Corporate Advisory Services: Kontafarma extends its expertise to offer corporate advisory services, guiding entities in navigating the complex landscape of the health sector. This service ensures companies can make informed decisions regarding investments, operations, and management within the health and wellness field.

Contact Information

Address: Sun Hung Kai Centre
Phone: 852 2731 6500